Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Cardiovascular Complications and Risk of Death in Sickle-cell Disease
source: Lancet
year: 2016
authors: Gladwin MT
summary/abstract:In sickle-cell disease, a point mutation in the β-globin chain causes haemoglobin to polymerise within erythrocytes during deoxygenation, altering red blood cell rheology and causing haemolysis. Improvements in health infrastructure, preventive care, and clinical treatments have reduced the morbidity and mortality of sickle-cell disease in developed countries. However, as these patients live longer, the chronic effects of sustained haemolytic anaemia and episodic vaso-occlusive events drive the development of end-organ complications. Cardiopulmonary organ dysfunction and chronic kidney injury have a large effect on morbidity and premature mortality, and typically accelerate in the second decade of life. These processes culminate in the development of pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, and sudden death. In this Series paper, we review the mechanisms, clinical features, and epidemiology of major cardiovascular complications in patients with sickle-cell disease and discuss how screening and intervention could reduce their incidence.
organization: Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, Division of Pulmonary, Allergy and Critical Care Medicine; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USADOI: 10.1016/S0140-6736(16)00647-4
read more full text
+myBinderRelated Content
-
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disea...Background: Sickle cell disease is a ...
-
Sickle Cell Trait, Disease Linked With Faster Kidney Function Decline in African American PatientsSickle-cell trait (SCT) and disease (SCD...
-
Vaso occlusive Crisis Pain Assessment & Managementhttps://www.youtube.com/watch?time_conti...
-
Acute Chest Syndrome – A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=wRzTQfhG...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Sickle cell and the kidneyhttps://www.youtube.com/watch?v=iK2aLzlc...
-
Roland B. Scott Memorial Symposium: I Want Somebody to LoveRoland B. Scott Symposium on Sickle Cell...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.